Clinical dose-escalation study of auto-gammadelta T cell therapy for multiple myeloma to investigate its safety and efficacy

Clinical dose-escalation study of auto-gammadelta T cell therapy for multiple myeloma to investigate its safety and efficacy - Clinical study of gammadelta T cell therapy for multiple myeloma

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000000554

Enrollment

Registered

2006-12-25

Start date

2006-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple myeloma

Interventions

Gammadelta T cell is to be administrated intravenously four times on a biweekly-basis.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Multiple myeloma patients who had received a series of induction chemotherapy before more than 8 weeks - Performance status 0-1 - No serious abnormality in bone marrow, liver and/or renal functions

Exclusion criteria

Exclusion criteria: Patients who have: uncontrolled infections, active autoimmune diseases, serious cardiac disease and other cancers; who have received continuous systemic steroids; who are pregnant, to be pregnant, or nursing mothers, and whom principle investigator or co-investigator judged to be inappropriate to participate in this study

Design outcomes

Primary

Measure	Time frame
Safety : Adverse events	—

Secondary

Measure	Time frame
Efficacy : Improvement and maintenance of tumor-related immuno/biochemistrical parameters	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026